FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149786788> ?p ?o ?g. }

• W2149786788 endingPage "92" @default.
• W2149786788 startingPage "84" @default.
• W2149786788 abstract "Specific antitumor immune responses require expression of MHC class I or II molecules on tumor cells, and MHC antigen down-regulation is a presumed tumor growth promoting mechanism. Because IFN-gamma up-regulates tumor MHC antigen expression in vitro, in this Phase II trial of an immunologically active dose and schedule we evaluated whether this was the case in vivo. Twenty-three patients with metastatic melanoma were treated with IFN-gamma 100 microg/m(2) s.c. once weekly for a maximum of 6 months. There were three complete responses, now maintained for 53, 36, and 25 months. The remainder had progressive disease. The treatment was well tolerated, with no toxicity exceeding National Cancer Institute Common Toxicity Criteria grade II. Immunohistochemical analysis of tumor biopsies during treatment was performed using monoclonal antibodies to HLA class I (W/632) and class II (CR3/43) monomorphic determinants. HLA class I was down-regulated in 2 of 19 patients pretreatment and up-regulated by IFN-gamma in both. HLA class II was down-regulated pretreatment in 14 of 18 patients and up-regulated by IFN-gamma in 6 (43%). The HLA up-regulation persisted throughout the study. IFN-gamma induced significant but short-lived up-regulation of surrogate markers of monocyte activation (serum neopterin) and class I up-regulation (serum beta-2-microglobulin) in most patients. There was no consistent relationship between surrogate marker up-regulation, tumor antigen up-regulation, and responses. The study shows that the significant immune modulation induced by IFN-gamma does not correlate with tumor responses and that the serum surrogate marker changes do not reflect tumor events. The durable and long-lived responses, clear demonstration of tumor MHC up-regulation, and low toxicity suggest that weekly IFN-gamma 100 microg/m(2) would be a useful addition to chemoimmunotherapeutic regimens." @default.
• W2149786788 created "2016-06-24" @default.
• W2149786788 creator A5018411240 @default.
• W2149786788 creator A5021253379 @default.
• W2149786788 creator A5024251435 @default.
• W2149786788 creator A5026745416 @default.
• W2149786788 creator A5033223978 @default.
• W2149786788 creator A5040991512 @default.
• W2149786788 creator A5043000162 @default.
• W2149786788 creator A5059799734 @default.
• W2149786788 creator A5061389369 @default.
• W2149786788 creator A5071319458 @default.
• W2149786788 creator A5076812888 @default.
• W2149786788 creator A5082229478 @default.
• W2149786788 date "2003-01-01" @default.
• W2149786788 modified "2023-10-12" @default.
• W2149786788 title "Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma." @default.
• W2149786788 cites W143127919 @default.
• W2149786788 cites W1488633144 @default.
• W2149786788 cites W1491325575 @default.
• W2149786788 cites W1590831917 @default.
• W2149786788 cites W1621456877 @default.
• W2149786788 cites W1858238123 @default.
• W2149786788 cites W1974718770 @default.
• W2149786788 cites W1989339760 @default.
• W2149786788 cites W1991478818 @default.
• W2149786788 cites W2013931012 @default.
• W2149786788 cites W2015742067 @default.
• W2149786788 cites W2018227907 @default.
• W2149786788 cites W2028405879 @default.
• W2149786788 cites W2034750454 @default.
• W2149786788 cites W2048582703 @default.
• W2149786788 cites W2065237340 @default.
• W2149786788 cites W2077137895 @default.
• W2149786788 cites W2078885983 @default.
• W2149786788 cites W2083325655 @default.
• W2149786788 cites W2085499336 @default.
• W2149786788 cites W2153914897 @default.
• W2149786788 cites W2167805334 @default.
• W2149786788 cites W2209896411 @default.
• W2149786788 cites W2324293153 @default.
• W2149786788 cites W2343701152 @default.
• W2149786788 cites W2408274267 @default.
• W2149786788 cites W2412065260 @default.
• W2149786788 cites W2412623942 @default.
• W2149786788 cites W2417679862 @default.
• W2149786788 cites W2422654307 @default.
• W2149786788 cites W2466046997 @default.
• W2149786788 cites W84647915 @default.
• W2149786788 cites W2423181230 @default.
• W2149786788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12538455" @default.
• W2149786788 hasPublicationYear "2003" @default.
• W2149786788 type Work @default.
• W2149786788 sameAs 2149786788 @default.
• W2149786788 citedByCount "45" @default.
• W2149786788 countsByYear W21497867882012 @default.
• W2149786788 countsByYear W21497867882013 @default.
• W2149786788 countsByYear W21497867882015 @default.
• W2149786788 countsByYear W21497867882016 @default.
• W2149786788 countsByYear W21497867882017 @default.
• W2149786788 countsByYear W21497867882018 @default.
• W2149786788 countsByYear W21497867882019 @default.
• W2149786788 countsByYear W21497867882020 @default.
• W2149786788 countsByYear W21497867882021 @default.
• W2149786788 countsByYear W21497867882022 @default.
• W2149786788 countsByYear W21497867882023 @default.
• W2149786788 crossrefType "journal-article" @default.
• W2149786788 hasAuthorship W2149786788A5018411240 @default.
• W2149786788 hasAuthorship W2149786788A5021253379 @default.
• W2149786788 hasAuthorship W2149786788A5024251435 @default.
• W2149786788 hasAuthorship W2149786788A5026745416 @default.
• W2149786788 hasAuthorship W2149786788A5033223978 @default.
• W2149786788 hasAuthorship W2149786788A5040991512 @default.
• W2149786788 hasAuthorship W2149786788A5043000162 @default.
• W2149786788 hasAuthorship W2149786788A5059799734 @default.
• W2149786788 hasAuthorship W2149786788A5061389369 @default.
• W2149786788 hasAuthorship W2149786788A5071319458 @default.
• W2149786788 hasAuthorship W2149786788A5076812888 @default.
• W2149786788 hasAuthorship W2149786788A5082229478 @default.
• W2149786788 hasConcept C147483822 @default.
• W2149786788 hasConcept C170627219 @default.
• W2149786788 hasConcept C188280979 @default.
• W2149786788 hasConcept C203014093 @default.
• W2149786788 hasConcept C207936829 @default.
• W2149786788 hasConcept C2777658100 @default.
• W2149786788 hasConcept C502942594 @default.
• W2149786788 hasConcept C71924100 @default.
• W2149786788 hasConcept C86803240 @default.
• W2149786788 hasConcept C8891405 @default.
• W2149786788 hasConceptScore W2149786788C147483822 @default.
• W2149786788 hasConceptScore W2149786788C170627219 @default.
• W2149786788 hasConceptScore W2149786788C188280979 @default.
• W2149786788 hasConceptScore W2149786788C203014093 @default.
• W2149786788 hasConceptScore W2149786788C207936829 @default.
• W2149786788 hasConceptScore W2149786788C2777658100 @default.
• W2149786788 hasConceptScore W2149786788C502942594 @default.
• W2149786788 hasConceptScore W2149786788C71924100 @default.
• W2149786788 hasConceptScore W2149786788C86803240 @default.

• next